Client references
Immunovia: € 4.25M
The Horizon 2020 experts in GAEU proved to be very efficient and professional in their work and had great commitment and interest in our project which resulted in a grant of EUR 4.25 million.
Cellink AB: € 2.5M
The company focuses on the development and commercialization of bioprinting technologies that allow researchers to 3D print human organs and tissues for the development of pharmaceutical and cosmetic products, and in the future, for clinical applications. Cellink was granted € 2.5M from the SME Instrument HORIZON 2020, phase 2. “Collaborating with GAEU has been…
Cinnober: € 2.5M
We are very pleased with GAEU Consulting’s work! Together with GAEUs advisors, we have managed to win in fierce competition with other European companies.
Betagenon: € 1.8M
In the application process, GAEU Consulting has proven itself to be a first class life science advisor, showing excellent understanding of our candidate drug and forces driving commercialization of medicinal products.
Nelson Garden: € 1.2M
I really would like to recommend GAEU to anyone who is interested in applying for Horizon 2020 funding.
CombiGene AB: € 3.3M
By combining modern neuroscience with recent advances in gene delivery, CombiGene has developed a method shown to suppress epileptic seizures in preclinical studies. CombiGene was granted €3.3 million from the SME Instrument HORIZON 2020, phase 2. “GAEU has in a significant way contributed to the successful outcome of our Horizon 2020-application. Both their experience…
SenzaGen: € 2.4M
At SenzaGen, we have strong ambitions to grow and enable animal-free, cell-based systems to assess hazards and potency of industrial compounds.
Corline Biomedical AB: € 2.3M
Corline, founded in 1991, develops, manufactures and markets heparin based solutions to improve kidney transplantation, cell therapies and applications in the evolving field of regenerative medicine. Coreline was granted € 2.3M from the SME Instrument HORIZON 2020, phase 2. “This is absolutely fantastic for Corline! This grant is one of the highest allocations awarded…
Opsis: € 2.3M
GAEU analyzed the situation, gave us valuable feedback which resulted in a grant of EUR 2.3 million for development of a new solution for analysis in the food industry.
Clinical Laserthermia Systems: € 2.1M
We are very pleased to be granted Horizon 2020 funding. This significant amount of money, EUR 2.1, will be spent on the validation of imILTCLS.
About Gaeu
GAEU Consulting is a professional service consultancy specializing in advising innovative companies on how to obtain EU grants to projects and growth activities
News
Horizon 2020 trumps national public funding in Poland
If you´re a Polish entrepreneur in the innovation sector with experience only in national public funding, this article is for you! It clearly presents the Horizon 2020 advantage over national funding programmes available in Poland.
Cellink and Klaria receives €4,5 Million from the Horizon 2020 SME Instrument Phase 2
GAEU Consulting’s clients Cellink and Klaria receives €4,5 Million from the Horizon 2020 SME Instrument Phase 2
H2020 SME Instrument: New Phase 1 record by GAEU Consulting
In this year’s second Horizon 2020 SME Instrument Phase 1 call (cut-off 3rd of May), GAEU Consulting wrote eight approved applications (excl another three so called runner up-applications).
GAEU Consulting’s client CombiGene receives €3,3 milion from the Horizon 2020 SME Instrument
CombiGene was granted 3,3 million euro in the latest Phase 2 round in the HorizonCombiGene was granted 3,3 million euro in the latest Phase 2 round in the Horizon2020 SME Instrument programme. GAEU Consulting wrote the EU application andguided the research company through the application procedure.
GAEU Consulting’s clients TLA and Xzero receives €4 Million from the Horizon 2020 SME Instrument
In the latest call for the phase 2 of the SME Instrument GAEU Consulting wrote two of four approved applications for Swedish innovation companies. GAEU´s customers received a total of 4 million euro.
Articles
The EIC SME Instrument New Work Programme = new possibilities
Biopharmaceuticals: New frontier
Laser-like focus on return on capital? A revamped project selection procedure
FOLLOW US ON TWITTER
Contact us
MSc, Michał Gadzinowski
+48 572 703 903
michal.gadzinowski@gaeu.pl
